Generate Biomedicines, Inc.
GENBNASDAQHealthcareBiotechnology
Previous close
$16.12
+$0.13 · +0.81%
Pre-market
$16.27
+$0.15 · +0.93%
Aug 24, 4:33 AM ET
GENB company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
57
Fair Value
Momentum
52
Neutral
Sentiment
56
Mixed
Risk resilience
55
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteGenerate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Michael T. Nally
- Listed since
- Feb 27, 2026
- Employees
- 312
Market position
Day range
Current $16.12
52-week range
Current $16.12
- Open
- $16.10
- Previous close
- $15.99
- Volume
- 831.85K
- 1.16× average
- Average volume
- 714.4K
- Average daily volume
- Market cap
- 2.07B USD
- Beta
- -0.14
- Market reference 1
- 50-day average
- $14.8314
- +8.69% above average
- 200-day average
- $13.7065
- +17.61% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 580.5M USD
- EV / EBITDA
- -2.78×
- Earnings yield
- -32.06%
- Free cash flow yield
- -32.22%
Profitability & efficiency
- Return on equity
- 32.98%
- Return on assets
- -61.53%
- Return on invested capital
- -89.38%
Financial health
- Current ratio
- 2.85×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 |
|---|---|---|
| Revenue | 31.89M USD | 20.46M USD |
| Gross profit | 31.89M USD | 20.46M USD |
| Research and development | 224.7M USD | 175.31M USD |
| Selling, general, and administrative | 42.26M USD | 42.09M USD |
| Operating expenses | 266.96M USD | 217.4M USD |
| Interest income | 13.66M USD | 18.12M USD |
| Interest expense | 1.14M USD | 2.12M USD |
| Depreciation and amortization | 13.18M USD | 15.35M USD |
| Operating income | −235.07M USD | −196.94M USD |
| Net income | −203.15M USD | −173.77M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 0%
- 0 beats, 1 miss, 0 met estimates
- Average EPS surprise
- -2.30%
- 1 comparable report
- Latest EPS result
- -0.52
- Estimate -0.51 · Miss by 2.30%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$23.50
45.78% upsideRecent analyst actions
GENB news
GENB peers
ETFs holding GENB
Funds reporting this stock among their holdings, ordered by reported position size.
ARK Genomic Revolution ETFARKG20.77M1.00%1.56B USD0.75%$49.45+3.80%
Vanguard Morningstar Total Stock Market ETFVTI11.44M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 ETFIWM9.73M0.01%81.62B USD0.19%$299.96+0.77%
Vanguard Extended Market ETFVXF4.16M0.00%93.7B USD0.05%$245.53+0.82%
iShares Russell 2000 Growth ETFIWO2.52M0.02%15.16B USD0.24%$387.37+1.24%
ALPS Medical Breakthroughs ETFSBIO2.42M1.02%236.37M USD0.50%$69.11+0.80%
Schwab U.S. Small-Cap ETFSCHA1.94M0.01%23.1B USD0.03%$34.83+0.52%
Vanguard Russell 2000 ETFVTWO1.92M0.01%17.4B USD0.06%$121.25+0.74%ARK Genomic Revolution ETFARKG- Market value
- 20.77M
- Weight
- 1.00%
- AUM
- 1.56B USD
- Expense ratio
- 0.75%
- Price / 1D
- $49.45+3.80%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 11.44M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 ETFIWM- Market value
- 9.73M
- Weight
- 0.01%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Extended Market ETFVXF- Market value
- 4.16M
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Russell 2000 Growth ETFIWO- Market value
- 2.52M
- Weight
- 0.02%
- AUM
- 15.16B USD
- Expense ratio
- 0.24%
- Price / 1D
- $387.37+1.24%
ALPS Medical Breakthroughs ETFSBIO- Market value
- 2.42M
- Weight
- 1.02%
- AUM
- 236.37M USD
- Expense ratio
- 0.50%
- Price / 1D
- $69.11+0.80%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 1.94M
- Weight
- 0.01%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
Vanguard Russell 2000 ETFVTWO- Market value
- 1.92M
- Weight
- 0.01%
- AUM
- 17.4B USD
- Expense ratio
- 0.06%
- Price / 1D
- $121.25+0.74%
Continue in GoAI
Research GENBresearch.disclaimer